Chris Lemmon 🍋

Thoracic and H&N oncology @uc_health #LCSM | Product of @ClevelandClinic and @MCG_AUG | Opinions = mine

[Chris Lemmon 🍋 @LemmonOnc]

Can't recommend voting for Nate enough. Not just a great lung cancer doc and leader in the field, but a fantastic personal mentor who has guided and elevated my career.

[ASCO @ASCO]

Voting in the ASCO Election is open now until December 3! Meet the candidates for the Board of Directors – Undesignated Member seat. Learn more about each candidate, determine your voting eligibility, and make your voice heard at https://t.co/dvxay4gojm

[Chris Lemmon 🍋 @LemmonOnc]

Great catching up with the old #CleClinicCancer TeamLung group at #WCLC24, and @LukasDelasos closing it out with his talk on radiomics. @LoganRoofMD @BMuthusamyMD

[Nathan A. Pennell MD, PhD, FASCO @n8pennell]

Excited to see our paper "Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non–Small-Cell Lung Cancer in the United States" in #lungcancer #LCSM in @JCOPO_ASCO top 5! https://t.co/zVaApU0BXN @LemmonOnc

[Stephen V Liu, MD @StephenVLiu]

PACIFIC-2 does not meet PFS endpoint. Phase III study of concurrent chemoradiation + duvalumab vs CRT alone for stage III NSCLC. Toxicity? Negative interaction? Or due to intrinsically different population: PACIFIC enrolled only those who completed CRT.

https://t.co/RxsPVfJrpR

[Chris Lemmon 🍋 @LemmonOnc]

@StephenVLiu Saw similar things in recent concurrent chemo/IO/RT trials in H&N where they’re now looking to sequential trials. Negative concurrent interaction seems likely.

[Chris Lemmon 🍋 @LemmonOnc]

@n8pennell @JackWestMD LAURA will complicate this even more if positive. Suspect we'll see some momentum to indefinite therapy in the resected setting in the coming years before we get good evidence for de-escelation or avoidance strategies

[Lukas Delasos @LukasDelasos]

Swing by #AACR23 section 42 today and check out our study evaluating survival with pembro for recurrent NSCLC s/p adj durva!! @CleClinicMD @n8pennell @Pradnya_PatilMD

[JCO Oncology Practice @JCOOP_ASCO]

#Immunotherapy & targeted therapy in the periop setting have demonstrated improved disease-free or event-free survival in biomarker-defined subsets of pts w #LungCancer. This review by @dipeshuprety4 @JackWestMD summarizes the evidence. ➡️ https://t.co/LbUze9YcTt #lcsm #immunoonc

[Bharathi Muthusamy @BMuthusamyMD]

🗞️Our study evaluating the use of comprehensive genomic profiling (CGP) in early stage lung adenocarcinoma is in the April issue of JTO!

Here is a brief overview of some of the highlights.

https://t.co/s2CHIyFTju

@n8pennell @geoff_oxnard @RichardHuangMD

#lcsm

[Madeline Waldron, PharmD, BCOP @MWaldronPharmD]

Can we start idolizing those who #chasebalance instead of those who chase it all?

[Madeline Waldron, PharmD, BCOP @MWaldronPharmD]

We live in a society that glorifies people with unhealthy boundaries. We applaud their nonstop work ethic & congratulate them on “doing it all” until slowly their productivity becomes our new standard - at home, at work, in life. 🧵

[Stephen V Liu, MD @StephenVLiu]

Phase II @CDNCancerTrials IND.227 trial @JTOonline. Phase II study compared chemo (platinum + pemetrexed) to chemo + pembro to pembro alone in pts with mesothelioma. Pembro + chemo offered higher RR (47% vs 19%) and OS (20m vs 9m) than chemo alone.

https://t.co/a2KNMy6DJ1

[Layan Alrahmani, MD, FACOG @DrAlrahmani]

It costs hospitals $250,000 to $1 million to replace one physician (who quits for burnout, lack of compensation, better opportunity, etc.) Why hospitals rather spend this $ on recruitment than on making their own employed physicians happy is beyond me.

[Chris Lemmon 🍋 @LemmonOnc]

Denial of frontline carbo/pem/pembro for a new stage IV lung adeno with no targets and PD-L1 40%. Is there any justification for that?

[Chris Lemmon 🍋 @LemmonOnc]

@WellcarePlans done

[Chris Lemmon 🍋 @LemmonOnc]

@Humana @WellcarePlans My patient's standard of care treatment was denied & I've tried to use the online service and have been transferred to 8 different people now to try to file an appeal and getting nowhere. This has been a month delay his care now.

[Chris Lemmon 🍋 @LemmonOnc]

@WellcarePlans Yeah I've done both of those things and talked to multiple people over the phone. Please help me file an appeal directly if possible.

[Chris Lemmon 🍋 @LemmonOnc]

Please tell me how I can get my patient the care he deserves.

[ALK+ International @ALKpositiveINT]

Researchers analysed the Medicaid Drug Utilization Database between 2020-21 & found that EGFR & ALK targeted therapies were used in only 66% of eligible patients.

“This underuse could have led to an estimated 855 prevented years of life lost.” 👇

https://t.co/PuulkwGPRG #LCSM

[Chris Lemmon 🍋 @LemmonOnc]

Had a peer2peer for prior auth today only to find out he's a @ClevelandClinic oncologist #CleClinicCancer. Surprising and unfortunate to me that someone working for the institution I trained at and that I respect would be looking to deny patients care they need. #FixPriorAuth